共 50 条
- [21] Cytogenetic Risk Stratification in Primary Versus Post-Essential Thrombocythemia / Post-Polycythemia Vera MyelofibrosisBLOOD, 2016, 128 (22)Masarova, LuciaBose, PrithvirajDaver, Naval G.Pemmaraju, NaveenNewberry, Kate J.Cortes, Jorge E.Kantarjian, Hagop M.Verstovsek, Srdan
- [22] Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statementWiener klinische Wochenschrift, 2017, 129 : 293 - 302Thamer SliwaChristine Beham-SchmidSonja BurgstallerVeronika Buxhofer-AuschGünther GastlKlaus GeisslerMaria KrauthPeter KripplAlois LangAndreas PetzerStefan WöhrerAlbert WölflerHeinz Gisslinger
- [23] A RUXOLITINIB INDIVIDUAL SUPPLY PROGRAM FOR PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)HAEMATOLOGICA, 2012, 97 : 321 - 321Barosi, G.Linardi, C.Ben Yehuda, D.Henrique Daumas Gabriel, A.Perez, J.Modi, A.Khan, M.Zweegman, S.Raymakers, R.Vianelli, N.Pakstyte, S.Willenbacher, W.Gisslinger, H.
- [24] Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosisLEUKEMIA, 2017, 31 (12) : 2851 - 2852Tefferi, A.Saeed, L.Hanson, C. A.Ketterling, R. P.Pardanani, A.Gangat, N.
- [25] A phase 1 study of XL019 a selective JAK2 inhibitor, in patients with primary myelofibrosis and, post-polycythemia vera/essential thrombocythemia myelofibrosisBLOOD, 2007, 110 (11) : 170A - 170AVerstovsek, SrdanPardanani, Animesh D.Shah, Neil P.Sokol, LubomirWadleigh, MarthaGilliland, D. GaryList, Alan F.Tefferi, AyalewKantarjian, Hagop M.Bui, Lynne A.Clary, Douglas O.
- [26] COMPASSIONATE USE PROGRAM (CUP) WITH RUXOLITINIB IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)HAEMATOLOGICA, 2013, 98 : 765 - 766Vargas, P.Karpovitch, X.Alvarado, M.Ovilla, R.Agreda, G.Guzman, P.Solis, J.Kassack, J.Silva, S.Zavala, S.Morales, J.Herrera, A.Reynoso, E.Rodriguez, M.Ruiz, G.Sobrevilla, P.Garcia, M.Aguilar, C.Morales, R.Barrera, E.Osuna, A.Carrillo, R.Silos, G.Vega, A.Cuin, S.Mora, M.Best, C.Murillo, E.Loarca, L.Perez, O.Salazar, J.Baez, E.Montemayor, J.Barrera, D.Garcia, J.Peraza, L.Baltazar, S.Iniguez, L.Oseguera, R.Nacho, K.Romero, T.
- [27] Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosisVIRCHOWS ARCHIV, 2021, 479 (04) : 755 - 764Guy, AlexandreBidet, AudreyLing, CatherineCaumont, CharlineBoureau, LisaViallard, Jean-FrancoisParrens, Marie
- [28] Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosisVirchows Archiv, 2021, 479 : 755 - 764Alexandre GuyAudrey BidetCatherine LingCharline CaumontLisa BoureauJean-François ViallardMarie Parrens
- [29] Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia MyelofibrosisJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5587 - 5593Tam, Constantine S.Kantarjian, HagopCortes, JorgeLynn, AlicePierce, SherryZhou, LingshaKeating, Michael J.Thomas, Deborah A.Verstovsek, Srdan
- [30] An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF)BLOOD, 2012, 120 (21)Barosi, GiovanniAgarwal, MohanZweegman, SonjaWillenbacher, WolfgangPakstyte, SimaRaymakers, ReinierCantoni, NathanModi, AnkurKhan, MahmudulPerez, Jose RicardoHasselbalch, HansVargas Viveros, Jose PabloLinardi, Camila C. G.Gisslinger, HeinzDaumas Gabriel, Adelmo HenriquePalandri, FrancescaLavie, DavidHarrison, Claire N.